A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Jan Stefan Scheld to Helm Nippon Boehringer Ingelheim
July 5, 2023
-
BUSINESS Chugai Is Best-Paying Japan Pharma Again in FY2022, 5 Drug Makers Top 10 Million Yen
July 4, 2023
-
REGULATORY MHLW to Launch Pharma Affairs Study Group July 10, Drug Loss Up for Debate
July 4, 2023
-
REGULATORY LDP Bigwigs Launch Study Group on Drug Discovery to Spur Innovation
July 3, 2023
-
BUSINESS 32 Pharma Execs Take Home Over 100 Million Yen in FY2022, Top 3 from Takeda: Securities Reports
July 3, 2023
-
REGULATORY MHLW Expert Panel’s Report Serves as Starting Line for Reform: Asst. Vice Minister
June 30, 2023
-
REGULATORY Japan Mulls Narrowing Down COVID-19 Jabs to Pfizer, but Some Lawmakers Are Skeptical
June 29, 2023
-
BUSINESS Chugai Trims 150 Reps via Voluntary Buyout, Sales Force Down to 1,050 from July
June 29, 2023
-
REGULATORY MHLW Shuffles Senior Bureaucrats, Jo Tapped as Chief of Pharma Bureau
June 28, 2023
-
BUSINESS Amgen Japan to Cut 30 Jobs in Evenity Sales Unit as It Rejigs Organization
June 27, 2023
-
BUSINESS Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
June 27, 2023
-
ORGANIZATION FPMAJ Chief Shows Enthusiasm toward Drug Pricing Reform, Vows to Exchange Views with All Affiliate Groups
June 26, 2023
-
ORGANIZATION New JPMA Director General Keen to Make “Special Price Maintenance” Happen after 15 Years
June 23, 2023
-
REGULATORY Chuikyo Kicks Off Debates toward FY2024 Drug Price Reform
June 22, 2023
-
COMMENTARY Honebuto Policy Is Tailwind for Pharma, but Situation Remains Unpredictable
June 22, 2023
-
REGULATORY MHLW to Set Up Separate Forums Focused on Generics and Drug Lags to Execute Expert Panel Proposals
June 21, 2023
-
BUSINESS Wegovy Rollout Being Delayed due to Unprecedented Demand: Novo Japan Chief
June 21, 2023
-
REGULATORY MHLW Study Group to Develop Company Indicators for Generic Supply Systems in FY2023
June 20, 2023
-
REGULATORY MHLW Study Group Proposes Flexibility in Launch Premium Criteria, Broader Comparators
June 20, 2023
-
REGULATORY Japan OKs Honebuto Budget Policy Blueprint, Vows Debates on Longer-Term Drug Costs
June 19, 2023
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…